Abstract
Abstract
Background
Lung cancer remains one of the most lethal carcinomas worldwide because of its late diagnosis. One of the DNA modifications is methylation, one of the primary alterations of tumor development, consisting of fascinating indicators for cancer diagnosis. This study investigated ZMYND-8 and RARβ2 gene methylation in NSCLC as a new epigenetic tool.
Methods
First, to find out the potential diagnostic capability of ZMYND-8 and RARβ2 genes methylation, we entirely surfed DNA methylation microarrays from the Cancer Genome Atlas (TCGA) data of NSCLC samples. Additionally, we took advantage of using q-MSP in several pieces comprising NSCLC tumors and neighboring normal tissues; ZMYND-8 and RARβ2 genes methylation grades were acquired.
Results
Our finding displayed significant hypomethylation of ZMYND-8 and hypermethylation of RARβ2 in NSCLC samples compared to neighboring standard specimens, which significantly correlated with the clinical stage of malignancy. In addition, the incredible precision of ZMYND-8 and RARβ2 methylations as reliable cancer diagnosis indicators in NSCLC was confirmed, drawing the ROC curve analysis with an AUC value of 0.751 and 0.8676, respectively, for ZMYND-8 and RARβ2. Additional studies of other dominant cancer entities in TCGA displayed that RARβ2’s higher methylation degree and ZMYND-8 lower methylation degree are prevalent changes in tumor evolution which could be possibly considered as a potential diagnostic biomarkers for lung cancer.
Conclusion
Based on this study, ZMYND-8 and RARβ2 methylation are reliable biomarkers for lung cancer.
Funder
Tabriz University of Medical Sciences
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Zarredar H, Pashapour S, Farajnia S, Ansarin K, Baradaran B, Ahmadzadeh V, Safari F (2019) Targeting the KRAS, p38α, and NF-κB in lung adenocarcinoma cancer cells: the effect of combining RNA interferences with a chemical inhibitor. J Cell Biochem 120(6):10670–10677
2. Zarredar H, Farajnia S, Ansarin K, Baradaran B, Aria M, Asadi M (2019) Synergistic effect of novel EGFR inhibitor AZD8931 and p38α siRNA in lung adenocarcinoma cancer cells. Anti-Cancer Agents Med Chem Former Curr Med Chem-Anti-Cancer Agents 19(5):638–644
3. Mastoraki S, Lianidou E (2017) DNA and histone methylation in lung cancer. In: Kaneda A, Tsukada YI (eds) DNA and histone methylation as cancer targets. Springer, pp 403–436
4. Shanehbandi D, Asadi M, Seyedrezazadeh E, Zafari V, Shekari N, Akbari M, Rahbarnia L, Zarredar H microRNA-based biomarkers in lung cancer: recent advances and potential applications. Current Molecular Medicine
5. Langevin SM, Kratzke RA, Kelsey KT (2015) Epigenetics of lung cancer. Transl Res 165(1):74–90